The non-dilutive financing removes near-term dilution risk and funds the company through three major clinical catalysts over the next 12 months. The Phase 3 AURORA readout in 1Q27 is the primary value driver — a positive result could validate Descartes-08 as a best-in-class outpatient CAR-T for autoimmune disease. Monitor enrollment updates and any safety signals from ongoing trials.
Price Chart
Executive Summary
Cartesian Therapeutics secured a $150M non-dilutive credit facility from K2 HealthVentures, with an initial $50M tranche funded, extending cash runway into 2028. The company also provided updated timelines for key clinical catalysts: Phase 3 AURORA topline data in myasthenia gravis expected in 1Q27, with BLA filing mid-2027; Phase 2 TRITON data in myositis and Phase 1/2 HELIOS data in juvenile dermatomyositis both expected in 1H27. The CMO is stepping down, but the company's R&D head will continue overseeing trials through BLA filing.
Key Financial Metrics
Key Facts
- Secured up to $150M non-dilutive credit facility from K2 HealthVentures; initial $50M tranche funded upon signing.
- Cash runway extended into 2028, supporting three near-term clinical catalysts and pre-launch activities.
- Phase 3 AURORA topline data in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027.
- Phase 2 TRITON data in myositis expected in 1H27; Phase 1/2 HELIOS data in juvenile dermatomyositis expected in 1H27.
- CMO Miloš Miljković stepping down; R&D head Peter Traber to continue supporting trials through BLA filing.
- Descartes-08 is the only CAR-T in autoimmune disease designed for outpatient administration without preconditioning chemotherapy.
Financial Impact
Up to $150M credit facility, with $50M funded immediately, extending cash runway into 2028.
Risk Factors
- Phase 3 AURORA trial may fail to meet primary endpoint, significantly impairing Descartes-08's prospects.
- CMO departure could create temporary leadership gap, though R&D head remains.
- Additional tranches of credit facility are contingent on achieving clinical and regulatory milestones.
- Competition from other CAR-T therapies in autoimmune indications (e.g., from BMS, Kyverna).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300928 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $7.24 $7.21 | ▼ −0.41% | ▼ −0.21% | $6.28 (−13.26%) |
Aug 6, 2026 11w ago | 8-K | $8.76 $8.85 | ▲ +1.03% | ▲ +0.42% | $6.28 (−28.31%) |
May 26, 2026 21w ago | 8-K | $5.84 $5.86 | ▲ +0.34% | ▲ +0.12% | $6.28 (+7.53%) |
May 26, 2026 21w ago | Press Release | $6.45 $6.93 | ▲ +7.44% | ▲ +7.43% | $6.28 (−2.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers